Biochemistry · 2000 · 81 citations · 17 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMolecular OncologyCytotoxic ChemotherapyDna Damage-induced ApoptosisMolecular Mechanisms Of ToxicityTopoisomerase InhibitorsAnticancer ActivityCleavage SpecificityDna CleavageDna Cleavage MechanismNon-small Cell Lung Cancer TreatmentTopoisomerase ActivityTopoisomerase Ii FunctionTopoisomerase-mediated Dna Breaks
TOP-53 is a promising anticancer agent that displays high activity against non-small cell lung cancer in animal tumor models [Utsugi, T., et al. (1996) Cancer Res. 56, 2809-2814]. Compared to its parent compound, etoposide, TOP-53 is considerably more toxic to non-small cell lung cancer cells, is more active at generating chromosomal breaks, and displays improved cellular uptake and pharmacokinetics in animal lung tissues. Despite the preclinical success of TOP-53, several questions remain regarding its cytotoxic mechanism. Therefore, this study characterized the basis for drug action. Results indicate that topoisomerase II is the primary cytotoxic target for TOP-53. Furthermore, the drug kills cells by acting as a topoisomerase II poison. TOP-53 exhibits a DNA cleavage site specificity that is identical to that of etoposide. Like its parent compound, the drug increases the number of enzyme-mediated DNA breaks by interfering with the DNA religation activity of the enzyme. TOP-53 is considerably more efficient than etoposide at enhancing topoisomerase II-mediated DNA cleavage and exhibits high activity against human topoisomerase IIalpha and IIbeta in vitro and in cultured cells. Therefore, at least in part, the enhanced cytotoxic activity of TOP-53 can be attributed to an enhanced activity against topoisomerase II. Finally, TOP-53 displays nearly wild-type activity against a mutant yeast type II enzyme that is highly resistant to etoposide. This finding suggests that TOP-53 can retain activity against systems that have developed resistance to etoposide, and indicates that substituents on the etoposide C-ring are important for topoisomerase II-drug interactions.
17
Molecular cloning: A laboratory manual
Prescott L. Deininger · Analytical Biochemistry · 1990 · 86.2K citations
Cancer chemotherapy and biotherapy: Principles and practice
L.E. Ellis · Surgical Oncology · 1997 · 423 citations
Medicine, Oncology, Pharmacotherapy +12
Kenneth N. Kreuzer, Nicholas R. Cozzarelli · Journal of Bacteriology · 1979 · 334 citations · Full text